Latest Ratios: P/E Ratio -1.3x · EV/EBITDA N/A · ROE -46.6%. (2018–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $114M | $56M | $307M | $617M | $798M | $1.3B | — | — |
| Enterprise Value | $31M | $-27225479 | $199M | $463M | $470M | $944M | — | — |
| P/E Ratio → | -1.32 | — | — | — | — | — | — | — |
| P/S Ratio | 2.14 | 1.04 | 6.01 | 4.68 | 104.95 | 9376.08 | — | — |
| P/B Ratio | 0.74 | 0.37 | 1.45 | 2.21 | 2.77 | 4.41 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 1915.13 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.51 | 3.90 | 3.51 | 61.90 | 6989.57 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.0% | 74.1% | 11.5% | -1056.0% | -28622.2% | — | — |
| Operating Margin | -174.9% | -174.9% | -227.3% | -15.0% | -1429.7% | -40223.7% | — | — |
| Net Profit Margin | -158.4% | -158.4% | -183.4% | -22.0% | -1406.7% | -39568.1% | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -46.6% | -46.6% | -38.2% | -10.2% | -37.2% | -28.4% | -80.7% | — |
| ROA | -39.4% | -39.4% | -30.4% | -7.9% | -29.5% | -23.2% | -46.7% | -102.6% |
| ROIC | -81.3% | -81.3% | -75.9% | -34.2% | — | — | — | — |
| ROCE | -51.1% | -51.1% | -46.5% | -6.4% | -32.0% | -24.4% | -46.7% | -106.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.01 | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.55 | -0.51 | -0.55 | -1.13 | -1.12 | -1.04 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($85M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.77 | 6.77 | 6.24 | 4.50 | 10.01 | 31.46 | 23.22 | 6.32 |
| Quick Ratio | 6.77 | 6.77 | 6.24 | 4.50 | 10.01 | 31.46 | 23.22 | 6.32 |
| Cash Ratio | 6.04 | 6.04 | 5.72 | 4.37 | 9.74 | 30.30 | 22.33 | 5.63 |
| Asset Turnover | — | 0.30 | 0.20 | 0.36 | 0.02 | 0.00 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 84.27 | 109.30 | 11.97 | 155.32 | 16665.63 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $42M | $42M | $42M | $38M | $37M | $37M | $16M |
Clinical milestone funding dependency
Based on reported figures, RPTX trades at a P/S multiple of 2.14, which appears to discount the company's platform potential significantly compared to peers like Revolution Medicine, suggesting that investors are pricing in the high probability of future dilutive capital raises to sustain clinical operations.
The current valuation reflects a market that is increasingly skeptical of the company's ability to generate independent value following the termination of key partnerships. Without recurring revenue or a clear path to commercialization, traditional multiples like P/E are non-meaningful, leaving the stock tethered to the speculative value of its DNA damage repair pipeline.
As reported in financial statements, the company's ROIC has fluctuated wildly, reaching a low of -37.8% in 2025Q1, which indicates that the capital deployed into the SNIPRx platform has yet to generate a positive return, reflecting the inherent inefficiency of pre-revenue clinical-stage biotechnology development.
The negative ROIC trend highlights the massive capital intensity required to advance clinical assets without the offset of commercial product sales. Investors should monitor whether the company can improve these returns through more selective pipeline prioritization or if the current burn rate will continue to erode shareholder value.
According to recent SEC filings, the company's asset turnover ratio remains negligible at 0.09 in 2025Q3, underscoring the lack of operational scale and the reliance on non-recurring milestone payments rather than a consistent, high-velocity revenue generation model typical of mature industrial or technology firms.
The extreme fluctuations in DSO, which reached 21,344 in 2025Q2, suggest that the timing of milestone collections is highly irregular and unpredictable. This lack of working capital efficiency forces the company to maintain higher cash buffers, further complicating the management of its limited liquidity position.
Based on reported figures, the current ratio of 10.71 in 2025Q3 appears superficially strong, yet this liquidity is rapidly being consumed by operating losses, leaving the company with a tightening runway that warrants further investigation into the necessity of near-term equity financing to maintain operations.
While the high current ratio suggests an ability to meet short-term obligations, the absence of recurring cash inflows means that the company is essentially living off its remaining cash reserves. The rapid decline in total assets over the last two years indicates that the company is effectively liquidating its balance sheet to fund R&D.
The most commonly misapplied metric for Repare is the gross margin, which, at 100% in 2025Q3, creates a false impression of profitability that ignores the massive, non-capitalized R&D expenses required to sustain the business model, thereby obscuring the company's true underlying cash-burn trajectory.
Investors should instead focus on the cash-burn rate and the cash runway ratio, as these metrics provide a more accurate assessment of the company's survival horizon. Relying on accounting-based margins in a pre-revenue biotech context is misleading, as it fails to account for the massive investment in clinical trials that are expensed immediately.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RPTX stock.
Repare Therapeutics Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
Repare Therapeutics Inc.'s return on equity (ROE) is -46.6%. The historical average is -40.2%.
Based on historical data, Repare Therapeutics Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Repare Therapeutics Inc. has 75.0% gross margin and -174.9% operating margin.